Connection

RADEK SKODA to Proto-Oncogene Proteins

This is a "connection" page, showing publications RADEK SKODA has written about Proto-Oncogene Proteins.
Connection Strength

2.097
  1. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood. 2011 Feb 10; 117(6):2075-6.
    View in: PubMed
    Score: 0.271
  2. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
    View in: PubMed
    Score: 0.251
  3. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
    View in: PubMed
    Score: 0.195
  4. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005 Nov 15; 106(10):3374-6.
    View in: PubMed
    Score: 0.185
  5. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
    View in: PubMed
    Score: 0.182
  6. A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem. 2004 Aug 27; 279(35):36397-404.
    View in: PubMed
    Score: 0.171
  7. A 2-kb c-mpl promoter fragment is sufficient to direct expression to the megakaryocytic lineage and sites of embryonic hematopoiesis in transgenic mice. Blood. 2002 Aug 01; 100(3):1072-4.
    View in: PubMed
    Score: 0.150
  8. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nat Commun. 2019 03 19; 10(1):1252.
    View in: PubMed
    Score: 0.119
  9. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci U S A. 1999 Jan 19; 96(2):698-702.
    View in: PubMed
    Score: 0.118
  10. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol. 1997 Apr; 11(4):393-9.
    View in: PubMed
    Score: 0.104
  11. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J. 1993 Jul; 12(7):2645-53.
    View in: PubMed
    Score: 0.080
  12. SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood. 2011 Jul 21; 118(3):723-35.
    View in: PubMed
    Score: 0.069
  13. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006 Sep 15; 108(6):1865-7.
    View in: PubMed
    Score: 0.049
  14. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005 Jul; 90(7):871-4.
    View in: PubMed
    Score: 0.046
  15. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005 Jan; 19(1):1-13.
    View in: PubMed
    Score: 0.044
  16. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003 Sep 01; 102(5):1869-71.
    View in: PubMed
    Score: 0.040
  17. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996 Jan 15; 87(2):567-73.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.